Bone Biologics (BBLG) Cash & Equivalents (2012 - 2026)

Bone Biologics (BBLG) has reported Cash & Equivalents for 14 consecutive years, with $5.3 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash & Equivalents rose 59.39% year-over-year to $5.3 million; the TTM figure through Dec 2025 stood at $5.3 million (up 59.39% YoY), while the FY2025 annual figure was $5.3 million, up 59.39% from the prior year.
• Cash & Equivalents retreated to $5.3 million in Q4 2025 per BBLG's latest filing, from $6.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $7.5 million in Q4 2022 and bottomed at $3374.0 in Q3 2021.
• Historically, Cash & Equivalents has averaged $4.2 million across 5 years, with a median of $4.8 million in 2022.
• Annual changes were most pronounced in 2022 — Cash & Equivalents jumped 149847.93% — and 2024, when it plunged 66.72%.
• Bone Biologics' Cash & Equivalents stood at $6.7 million in 2021, then rose by 12.93% to $7.5 million in 2022, then sank by 59.85% to $3.0 million in 2023, then climbed by 9.86% to $3.3 million in 2024, then jumped by 59.39% to $5.3 million in 2025.
• Business Quant data shows BBLG's Cash & Equivalents at $5.3 million in Q4 2025, $6.0 million in Q3 2025, and $6.6 million in Q2 2025.